## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)													
1. Name and Address of Reporting Person * MORRIS JESSICA EDGAR				2. Issuer Name and Ticker or Trading Symbol Tonix Pharmaceuticals Holding Corp. [TNXP]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner				
(Last) (First) (Middle) C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVENUE, SUITE 306				3. Date of Earliest Transaction (Month/Day/Year) 06/14/2018						X Officer (give title below) Other (specify below)  Chief Operating Officer					
(Street) NEW YORK, NY 10022				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person				
(City) (State) (Zip)				Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deem Execution any (Month/D	Date, if	Code (Instr. 8)	ction	tion 4. Securities Acquir (A) or Disposed of (D) (Instr. 3, 4 and 5)		of	d 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Following a(s)	Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	V	Amount	(A) or (D)	Price						
Common value	Stock, \$0.	001 par	06/14/2018			P		300	I A	\$ 4.19	1,638			D	
indirectly.			Table II - D	<b>D</b> erivative	Securiti		cont the f	ained in orm dis	this for plays a	rm are curre	e not req ntly valid	uired to re d OMB co	nformation espond unlo	ess	EC 1474 (9- 02)
1 77:4 6	2	2 55 43	,	<u> </u>		rrants, op	1 '				1.1 1	0 D : C	0.31 1	C 10	11.37
Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/	Year) Execution Da	4. Transaction Code Year) (Instr. 8)		of	6. Date Exercis and Expiration (Month/Day/Ye		n Date	Amo Und Secu	itle and ount of lerlying urities tr. 3 and		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownersh Form of Derivativ Security Direct (I or Indire	ve Ownership v: (Instr. 4) D) ect
				Со	de V	(A) (D)	Date		Expiration Date	n Title	Amount or Number of Shares				
Repor	ting O	wners													
							]	Relations	ships						
Reporting Owner Name / Address					Directo	Director 10% Owner Officer						her			

Chief Operating Officer

### **Signatures**

MORRIS JESSICA EDGAR

NEW YORK, NY 10022

/s/ Jessica Morris	06/14/2018
Signature of Reporting Person	Date

509 MADISON AVENUE, SUITE 306

C/O TONIX PHARMACEUTICALS HOLDING CORP.

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

#### Remarks

Reporting person may be deemed to be a control person of this entity.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.